Research programme: mitochondrial disease therapeutics - ElexoPharm/Khondrion/Pharmacelsus/Radboud UniversityAlternative Names: E!6654; MITOTREAT
Latest Information Update: 29 Jul 2016
At a glance
- Originator ElexoPharm GmbH; Khondrion; Pharmacelsus; Radboud University Nijmegen Medical Centre
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Mitochondrial disorders
Most Recent Events
- 24 Jul 2016 Early research is ongoing in Germany and the Netherlands